metronidazole IV
PreclinicalSmall molecule
Pfizermetronidazole IV is one of 6 small molecule programs targeting Complicated Appendicitis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Complicated Appendicitis
#DrugCompanyPhaseTrials
1Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Amoxicillin-Clavulanic Acid
TevaApproved
Antibiotics
MMelinta Therapeutics, Inc.
Approved
Antibiotic
PfizerPreclinical
metronidazole IV
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for metronidazole IV. EMBL-EBI & Wellcome Sanger Institute.
- [4]